01141-06 Species-Specific Differences in the Susceptibility of Biofilms Formed by Candida Bloodstream Isolates to Echinocandin Antifungals

[1]  L. J. Douglas,et al.  Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. , 2006, Journal of medical microbiology.

[2]  P. Tsang,et al.  Interspecies variation in Candida biofilm formation studied using the Calgary biofilm device , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  L. J. Douglas,et al.  Penetration of Candida Biofilms by Antifungal Agents , 2004, Antimicrobial Agents and Chemotherapy.

[4]  J. Perfect,et al.  Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species , 2004, Journal of Clinical Microbiology.

[5]  R. Darouiche,et al.  Candida Infections of Medical Devices , 2004, Clinical Microbiology Reviews.

[6]  M. Pfaller,et al.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. , 2004, Diagnostic microbiology and infectious disease.

[7]  M. Ghannoum,et al.  Candida biofilms: antifungal resistance and emerging therapeutic options. , 2004, Current opinion in investigational drugs.

[8]  J. Graybill,et al.  In Vitro Activity of Caspofungin against Candida albicans Biofilms , 2002, Antimicrobial Agents and Chemotherapy.

[9]  D. Kontoyiannis,et al.  Antifungal Activity of Amphotericin B, Fluconazole, and Voriconazole in an In Vitro Model of Candida Catheter-Related Bloodstream Infection , 2002, Antimicrobial Agents and Chemotherapy.

[10]  B. Wickes,et al.  In Vitro Pharmacodynamic Properties of Three Antifungal Agents against Preformed Candida albicans Biofilms Determined by Time-Kill Studies , 2002, Antimicrobial Agents and Chemotherapy.

[11]  M. Ghannoum,et al.  Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins , 2002, Antimicrobial Agents and Chemotherapy.

[12]  S. Suh,et al.  Biofilm Production by Isolates of Candida Species Recovered from Nonneutropenic Patients: Comparison of Bloodstream Isolates with Isolates from Other Sources , 2002, Journal of Clinical Microbiology.

[13]  M. Ghannoum,et al.  Comparison of Biofilms Formed by Candidaalbicans and Candidaparapsilosis on Bioprosthetic Surfaces , 2002, Infection and Immunity.

[14]  L. Saiman,et al.  Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.